Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide sold through Telegram channels, grey-market websites and unverified social sellers is not the same product you would receive from a GPhC-registered pharmacy. In the UK, tirzepatide (sold as Mounjaro) is a Prescription-Only Medicine — it cannot legally be supplied without a clinical assessment by a registered prescriber. The MHRA has confirmed repeatedly that fake and illegally traded weight-loss pens circulate widely online, and that some have caused serious harm. If you have seen tirzepatide advertised on Telegram with no mention of a prescription, that is a red flag, not a shortcut.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most dangerous assumption people make is that a grey-market product is simply the same medicine bought more cheaply. It is not. When tirzepatide changes hands through Telegram channels or unlicensed resellers, the chain of custody that guarantees the product's authenticity, temperature control and composition is broken. The UK's licensed supply chain runs from Eli Lilly through MHRA-regulated wholesalers to GPhC-registered pharmacies. Remove any link in that chain and you are left with a product that may look identical but could contain a different substance, a wrong dose, or nothing of clinical value at all.
Counterfeiting is not a theoretical risk here. MHRA enforcement teams raided an illicit manufacturing site in Northampton in October 2025 that was producing fake tirzepatide pens. The pens looked like genuine Mounjaro. They were not. Earlier operations uncovered hundreds of counterfeit pens that contained insulin, a medicine that, injected by someone without diabetes using a GLP-1 dose, could cause a life-threatening hypoglycaemic episode. The MHRA's Yellow Card scheme exists partly so that people who have received suspect products can report them, but that report comes after potential harm, not before.
The grey-market framing makes this sound like a regulatory technicality. It is not. The word 'grey' implies something on the edge of acceptable, but if you want to understand exactly what that grey-market ecosystem looks like in practice, our page on tirzepatide grey market supply covers how these networks operate and the specific risks they introduce. The reality is that selling a Prescription-Only Medicine through Telegram without a clinical assessment is illegal under the Human Medicines Regulations 2012, full stop. Buyers carry the risk that sellers do not.
A legitimate supply of tirzepatide in the UK begins with a prescriber reviewing your medical history, current medicines, BMI, and any conditions that might make the treatment unsuitable or require monitoring. That assessment exists because tirzepatide is not risk-free. It slows gastric emptying, affects how other medicines are absorbed, and is contraindicated in certain conditions. The NHS patient information for tirzepatide lists the full range of interactions and warnings that a prescriber is trained to work through before issuing a prescription.
Telegram sellers offer none of this. There is no consultation, no prescriber, no record of what you are taking or what else you have been prescribed. If something goes wrong (a reaction, a storage failure, a wrong dose) there is no clinical team to call and no regulated aftercare. Many grey-market listings also claim to offer dose-increase support, but a message from an anonymous account is not clinical guidance, and our page on Mounjaro being sold via Telegram explains in detail why those channels are unable to replicate any part of a real clinical service. Titrating tirzepatide without prescriber oversight removes the safety mechanism the schedule was designed around.
There is also the contraception question worth raising here. Tirzepatide can reduce the absorption of oral contraceptives, particularly during the first four weeks of treatment and around each dose increase. A prescriber flags this. A Telegram seller does not. If you are curious about what a proper eligibility assessment covers, the tirzepatide overview on the nume site walks through what the clinical review looks at.
If you are ever in doubt about an online pharmacy or seller claiming to supply tirzepatide, the check takes less than sixty seconds. Go to the GPhC's online pharmacy register, search the website's name or its stated registration number, and confirm it appears as a registered premises. Legitimate online pharmacies are required to display the EU common logo (a green cross with a flag) which links back to their GPhC entry. If it is not there, or if the search returns nothing, do not order. No legitimate seller will object to you making this check.
Telegram channels cannot appear on that register because they are not pharmacies. That is the simplest test of all: if the route to treatment does not pass through a registered pharmacy and a prescriber, it is not a legal or safe route. The grey-market Mounjaro page goes into more detail on how these supply networks are structured and why prices can look deceptively close to legitimate market rates.
For context on what private treatment through a regulated pharmacy actually costs and what is included, the Mounjaro market overview sets out the pricing landscape honestly. Understanding the price range makes it easier to spot listings that are too far below it to be credible.
Tirzepatide is available through two routes in the UK: the NHS, via a phased rollout with strict eligibility criteria, and private prescription from a GPhC-registered pharmacy following a clinical assessment. Neither involves Telegram. For people who do not meet current NHS thresholds or who do not want to wait, the private route is a completely legitimate option, but only when it runs through a registered prescriber and pharmacy.
The difference between a regulated private pharmacy and a Telegram seller is not primarily about cost. It is about accountability. A registered prescriber's name goes on the prescription. The pharmacy's GPhC number is verifiable. If something goes wrong, there is a regulatory body and a clinical team to answer to. None of that exists in a grey-market sale. The process of getting a legitimate Mounjaro prescription is more straightforward than many people expect, and understanding what it involves takes the guesswork out of it. Our clinical team reviews every consultation personally, a named prescriber, not an automated process, reads your answers before any prescription is issued.
If you have been sourcing tirzepatide through an unverified channel and want to move to a regulated supply, that conversation starts with a consultation. There is no obligation, and the clinical review covers your current situation including any doses you have been taking. Check your eligibility with a free consultation when you are ready.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.